SXTP

Business Context and Reporting Period

Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: A specialty pharmaceutical company focused on infectious diseases, primarily commercializing Arakoda (tafenoquine) for malaria prevention. The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased by 58.3% primarily due to the completion of a USAMMDA research contract in late 2025, which generated $92,731 in Q1 2025 but $0 in Q1 2026. Product revenue remained relatively flat, declining only 0.89%.
• Operating Expenses: Total operating expenses increased by 3.7% to $2.17 million. General and Administrative (G&A) expenses rose 9.7% driven by higher sales, advertising, and promotion costs ($521k vs $285k) and professional fees. Research and Development (R&D) expenses decreased 24.1% due to the absence of packaging validation costs incurred in the prior year.
• Liquidity Position: Cash balances increased from $1.51 million to $3.34 million, driven by net proceeds of approximately $3.37 million from At-The-Market (ATM) equity offerings. Net cash used in operating activities increased to $2.74 million.
• Stock Structure: The company effected a 1:4 reverse stock split effective January 20, 2026, to regain compliance with Nasdaq listing requirements. All prior period share data has been retroactively adjusted.

Guidance, Outlook, Risks, and Contingencies

• Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance. Current cash reserves are projected to sustain operations only through mid-September 2026 without additional capital.
• Capital Raising: The company raised approximately $3.37 million in Q1 2026 via ATM offerings. However, sales under the ATM agreement were suspended as of March 31, 2026, due to stock price declines limiting the company's public float capacity under Form S-3 rules.
• Derivative Liabilities: The company holds a derivative liability of $379,308 related to a contingent $10 million milestone payment to Knight Therapeutics, Inc., triggered by a sale of Arakoda or a Change of Control. This liability is marked-to-market quarterly.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting, citing inadequate policy design, lack of documentation, and insufficient segregation of duties. Consequently, disclosure controls were deemed ineffective.
• Business Developments: New partnerships were announced with Runway Health (telehealth) and GoodRx (prescription savings). Clinical trial results for babesiosis showed cures in all three enrolled patients. An NDIN for Australian Chestnut Extract was submitted to the FDA.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "mid-September 2026" liquidity projection given the suspension of ATM sales and high operating burn rate.
• ATM Capacity: Monitor stock price performance to determine when the company can resume equity sales under the ATM agreement to fund operations.
• Revenue Concentration: Note that 100% of receivables and 90% of product revenue come from a single significant U.S. distributor.
• Internal Controls: Assess the remediation plan for the material weaknesses in financial reporting controls disclosed in Item 4.
• Contingent Liabilities: Review the probability-weighted assumptions used to value the $10 million contingent milestone payment to Knight Therapeutics.